Tag archive for ‘bamlanivimab’
By pharmanewsdaily On Saturday, December 19th, 2020
0 Comments

Lilly to launch pragmatic study of Covid-19 drug candidate bamlanivimab in New Mexico

Eli Lilly and Company (Lilly) has revealed plans to launch a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with Covid-19, in partnership with major local institutions in New Mexico. The US More...

By pharmanewsdaily On Sunday, December 6th, 2020
0 Comments

Bamlanivimab Covid-19 drug candidate : Lilly, UnitedHealth Group join forces for pragmatic study

Eli Lilly and Company (Lilly) has entered into a partnership with managed care company UnitedHealth Group to carry out a pragmatic study of bamlanivimab (LY-CoV555) in high-risk, Covid-19 infected individuals. Recently, More...

By pharmanewsdaily On Tuesday, November 10th, 2020
0 Comments

Lilly’s Covid-19 candidate bamlanivimab gets FDA’s EUA

The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment More...

By pharmanewsdaily On Thursday, October 29th, 2020
0 Comments

Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt

Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, an investigational neutralizing antibody for the treatment of More...